-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Ovid Therapeutics, Raises Price Target to $7

Benzinga·03/20/2026 12:27:39
Listen to the news
Wedbush analyst Laura Chico maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $5 to $7.